1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,900 | 0,930 | 09:56 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROMIMIC Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 69,38 | -0,09 % | Medtronic warns on Harmony transcatheter pulmonary valve delivery system | ||
| HCA HEALTHCARE | 320,50 | +0,63 % | HCA surgery volumes dip in Q2, sending MedTech stocks lower | ||
| LANTHEUS | 89,80 | +0,22 % | Lantheus Holdings, Inc.: Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide) | BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| CAREDX | 25,200 | -0,79 % | Eurobio Scientific finalizes the acquisition of CareDX's transplant Lab Product division | EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio's strategic plan to become an in-vitro molecular diagnostics ("IVD") leaderCreation... ► Artikel lesen | |
| ENVISTA | 22,800 | 0,00 % | Does NVST Stock Still Deserve a Place in Your Portfolio? | ||
| GT BIOPHARMA | 0,363 | -1,73 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Third Quarter Fiscal Year 2026 Results | Reports 8.5% Increase in ARR to $22.1 Million, Net Income of $860,000 and 14% Year-over-Year Growth in Adjusted EBITDA
HENDERSON, Nev., May 14, 2026 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026.ISIN NameCA4013392051 GUARDIAN... ► Artikel lesen | |
| CHEMOMETEC | 55,65 | +1,83 % | Chemometec A/S: Growth in revenue and operating profit | Trading statement for Q3 2025/26 (1 January - 31 March 2026) Growth in revenue and operating profit ChemoMetec's revenue was up by 15% in the third quarter of 2025/26 to DKK 142.3 million from DKK... ► Artikel lesen | |
| POLAREAN IMAGING | 0,002 | 0,00 % | Polarean: Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 | ||
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): INSIDE INFORMATION - (1) DELAY IN PUBLICATION OF THE ANNUAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026 AND FURTHER DELAY IN PUBLICATION ... | ||
| DEVYSER DIAGNOSTICS | 5,460 | -1,80 % | Devyser Diagnostics AB: Sales in the second quarter of 2026 weaker than expected | Devyser Diagnostics AB (publ) (the "Company" or the "Group") announces that its preliminary sales for the second quarter of 2026 are weaker than indicated by the information and conditions available... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 69,68 | +0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| BILLIONTOONE | 124,59 | -0,22 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,210 | +0,05 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen |
PROMIMIC AB gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,895 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROMIMIC AB finden Sie auf Wallstreet Online.